Opus Point Partners Management as of Dec. 31, 2015
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 56 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares NASDAQ Biotechnology Index (IBB) | 7.1 | $11M | 32k | 338.32 | |
| Alkermes (ALKS) | 4.6 | $6.9M | 87k | 79.38 | |
| Ionis Pharmaceuticals (IONS) | 4.2 | $6.3M | 103k | 61.93 | |
| Alexion Pharmaceuticals | 4.2 | $6.3M | 33k | 190.75 | |
| Nektar Therapeutics (NKTR) | 3.9 | $5.9M | 349k | 16.85 | |
| Regeneron Pharmaceuticals (REGN) | 3.8 | $5.8M | 11k | 542.84 | |
| Amgen (AMGN) | 3.8 | $5.8M | 36k | 162.33 | |
| Celgene Corporation | 3.8 | $5.7M | 48k | 119.76 | |
| Seattle Genetics | 3.8 | $5.7M | 127k | 44.88 | |
| Bristol Myers Squibb (BMY) | 3.5 | $5.3M | 77k | 68.79 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.5 | $5.2M | 42k | 125.82 | |
| Incyte Corporation (INCY) | 3.4 | $5.2M | 48k | 108.44 | |
| Merck & Co (MRK) | 3.1 | $4.8M | 90k | 52.82 | |
| Alnylam Pharmaceuticals (ALNY) | 3.1 | $4.7M | 50k | 94.14 | |
| BioMarin Pharmaceutical (BMRN) | 3.0 | $4.6M | 44k | 104.76 | |
| Qiagen | 2.9 | $4.4M | 160k | 27.65 | |
| Medivation | 2.9 | $4.4M | 91k | 48.34 | |
| Illumina (ILMN) | 2.9 | $4.3M | 23k | 191.94 | |
| Gilead Sciences (GILD) | 2.2 | $3.4M | 34k | 101.19 | |
| Mettler-Toledo International (MTD) | 2.2 | $3.3M | 9.7k | 339.18 | |
| Biogen Idec (BIIB) | 2.1 | $3.2M | 11k | 306.33 | |
| Adamas Pharmaceuticals | 1.5 | $2.3M | 80k | 28.32 | |
| Agios Pharmaceuticals (AGIO) | 1.5 | $2.2M | 34k | 64.91 | |
| Epizyme | 1.4 | $2.2M | 136k | 16.02 | |
| Hologic (HOLX) | 1.2 | $1.9M | 48k | 38.69 | |
| Clovis Oncology | 1.2 | $1.8M | 50k | 35.00 | |
| Loxo Oncology | 1.1 | $1.7M | 60k | 28.45 | |
| Novavax | 1.1 | $1.7M | 200k | 8.39 | |
| AstraZeneca (AZN) | 1.1 | $1.7M | 49k | 33.95 | |
| Nanostring Technologies (NSTGQ) | 1.0 | $1.5M | 102k | 14.71 | |
| Pacira Pharmaceuticals (PCRX) | 1.0 | $1.5M | 19k | 76.77 | |
| Zogenix | 0.9 | $1.4M | 96k | 14.74 | |
| Ignyta | 0.9 | $1.3M | 100k | 13.40 | |
| Ophthotech | 0.9 | $1.3M | 17k | 78.53 | |
| Xencor (XNCR) | 0.9 | $1.3M | 90k | 14.62 | |
| Dicerna Pharmaceuticals | 0.8 | $1.2M | 100k | 11.87 | |
| Seres Therapeutics (MCRB) | 0.8 | $1.2M | 33k | 35.09 | |
| Paratek Pharmaceuticals | 0.8 | $1.1M | 60k | 18.97 | |
| Achillion Pharmaceuticals | 0.7 | $1.1M | 100k | 10.79 | |
| Proshares Tr pshs ult nasb (BIB) | 0.7 | $1.1M | 15k | 71.52 | |
| BioCryst Pharmaceuticals (BCRX) | 0.7 | $1.0M | 100k | 10.32 | |
| United Therapeutics Corporation (UTHR) | 0.7 | $1.0M | 6.5k | 156.59 | |
| Merrimack Pharmaceuticals In | 0.6 | $968k | 123k | 7.90 | |
| Medicines Company | 0.6 | $934k | 25k | 37.36 | |
| Macrogenics (MGNX) | 0.6 | $929k | 30k | 30.97 | |
| Vericel (VCEL) | 0.6 | $857k | 332k | 2.58 | |
| Karyopharm Therapeutics (KPTI) | 0.5 | $795k | 60k | 13.25 | |
| D Fluidigm Corp Del (LAB) | 0.5 | $757k | 70k | 10.81 | |
| Flamel Technologies | 0.5 | $693k | 57k | 12.20 | |
| Tokai Pharmaceuticals | 0.4 | $541k | 62k | 8.72 | |
| Pronai Therapeutics | 0.3 | $451k | 30k | 15.03 | |
| Axovant Sciences | 0.2 | $340k | 19k | 18.04 | |
| Dipexium Pharmaceuticals | 0.2 | $280k | 25k | 11.20 | |
| Infinity Pharmaceuticals (INFIQ) | 0.2 | $236k | 30k | 7.87 | |
| Carbylan Therapeutics Inc Common Stock Usd 0.001 | 0.0 | $63k | 18k | 3.60 | |
| Repros Therapeutics Inc *w exp 02/04/201 | 0.0 | $33k | 98k | 0.34 |
